Argus upgraded Laboratory Corp from Hold to Buy and set a new price target of $250.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2025 | $260.00 | Buy → Hold | HSBC Securities |
| 4/2/2025 | $276.00 | Buy | Redburn Atlantic |
| 3/4/2025 | $250.00 → $300.00 | Neutral → Buy | Citigroup |
| 1/7/2025 | $260.00 → $265.00 | In-line → Outperform | Evercore ISI |
| 12/10/2024 | $265.00 → $275.00 | Buy | Jefferies |
| 10/30/2024 | Hold → Buy | HSBC Securities | |
| 10/1/2024 | $235.00 | Neutral | Piper Sandler |
| 3/25/2024 | $250.00 | Hold → Buy | Argus |
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
Consumers Now Have More Choices to Purchase the Visby Device Featuring 30-Minute, Lab-Quality Results Today, Visby Medical announced two new relationships that will expand national access to the Visby Women's Sexual Health Test, the first, at-home, FDA-authorized PCR test for sexually transmitted infections (STIs) available to consumers, enabling immediate access to Visby's integrated "Test-to-Treat" ecosystem. The palm-sized device delivers confidential results in just 30 minutes, providing women with a rapid response for chlamydia, gonorrhea, and trichomoniasis from the comfort and privacy of the home. The need for accessible testing is urgent. Almost 100,000 women in the U.S. lose th
TOLEDO, Ohio, Jan. 8, 2026 /PRNewswire/ -- NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE:LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide. As a result of the acquisition, NAMSA assumes the U.S. portfolio of services of Labcorp's Ear
BURLINGTON, N.C., Dec. 30, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 13, at 4:30 p.m. PT. A live audio webcast of the fireside chat will be available via the Company Investor Relations website at ir.Labcorp.com and archived for replay. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmac
HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00
Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00
Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
3 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025. Bulto is an accomplished global executive with 25 years of experience in healthcare, and a proven track record of leadin
ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as
SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company's continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform. Aicher's expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executiv
TOLEDO, Ohio, Jan. 8, 2026 /PRNewswire/ -- NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE:LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide. As a result of the acquisition, NAMSA assumes the U.S. portfolio of services of Labcorp's Ear
Updates Full-Year Guidance Financial results from Operations for third quarter 2025 versus third quarter 2024:Revenue: $3.56 billion versus $3.28 billionDiluted EPS: $3.12 versus $2.00Adjusted EPS: $4.18 versus $3.50Updated Full-Year Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue guidance of 7.4% to 8.0%; midpoint lowered 40 bps due to currency and acquisition timingAdjusted EPS range of $16.15 to $16.50; midpoint raised by $0.05Free Cash Flow range of $1.17 billion to $1.29 billion; midpoint raised by $25 millionSigned several strategic agreements with health systems and regional/local laboratoriesAdvanced business in high-growth specialty testing areas, including onco
BURLINGTON, N.C., Oct. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 11, 2025, to stockholders of record as of the close of business on November 26, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)
SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)